Albarakati et al. [100] observed a synergy between cisplatin and two highly selective DNA-PKcs inhibitors, NU7026 and NU7441, in BRCA1-deficient breast cancer cell lines. The gene discussed is BRCA1; the disease is breast carcinoma.